51 results about "Ovarian ageing" patented technology

The invention discloses sturgeon ovary active peptide with ovary aging resistance and a preparation method of the sturgeon ovary active peptide. According to the invention, sturgeon ovary is taken as a raw material, and peptide with the highest ovarian aging resistance activity is selected from different enzymolysis combinations through an in-vitro anti-oxidation test and an ovarian granular cell and caenorhabditis elegans test; three sturgeon ovary active peptide sequences with ovary senescence resistance activity are screened by virtue of bioinformatics technologies such as mass spectrum identification, molecular docking and the like, and the amino acid sequences of the sturgeon ovary active peptide sequences are Phe-Met-Ile (FMI), Phe-Asp-Pro-Phe (FDPF) and Ser-Trp-Pro-Trp-Gln (SWPWQ). The sturgeon ovarian peptide prepared by the method not only has remarkable anti-premature ovarian failure activity and successfully solves the problem of high-valued utilization of sturgeon byproducts, but also can be used as a natural and efficient functional factor, is widely applied to functional products in the related fields of health care products, cosmetics, medicines and the like, and has a wide application prospect. And the method shows extremely wide market application prospects and huge economic values.

The invention discloses application of a substance for detecting the expression level of APOE or MT2 in evaluating the ovarian aging degree. According to the invention, cell and molecular changes related to ovarian aging are explored in spatial resolution by adopting a spatial transcriptome technology, a first non-human primate space-time transcriptome map is established, and potential diagnostic biomarkers and therapeutic targets of age-related human ovarian diseases are disclosed; the method not only promotes the understanding of primate ovarian aging mechanism determinants, but also provides abundant resources for identifying cells and molecular programs which can be used for evaluating ovarian aging and formulating intervention measures for human ovarian aging and related diseases.

The invention discloses application of MY-1B in preparation of medicines for improving ovarian aging, belongs to the technical field of biological medicines, and aims to solve the problems of how to effectively delay ovarian aging and improve ovarian functions. Experiments prove that the mRNA m5C modification level of ovarian granular cells in the ovarian aging process is increased, and the expression level of methylated transferase Nsun2 is increased. Ovarian aging caused by mRNA m5C modification level increase can be improved by supplementing the MY-1B, which is embodied in that the MY-1B can reduce the mRNA m5C modification level of aging nest granular cells; the MY-1B can be used for effectively correcting the orbital cycle disorder of the aged ovary and delaying the decline of the ovarian function; the MY-1B plays an important role in reducing the apoptosis level of granulosa cells in senescent ovaries; the MY-1B can improve the storage capacity of ovaries and enhance the quality of oocytes, so that the fertilization rate and the embryonic development potential of the oocytes are improved.

The invention discloses a health-care food for delaying ovarian aging, which belongs to the technical field of health-care foods and comprises a composition for improving the levels of anti-mullerian test tube hormone and superoxide dismutase and functional auxiliary materials, the composition for improving the anti-muller test tube hormone and superoxide dismutase level is prepared from the following components in parts by weight: 2 to 5 parts of pyrroloquinoline quinone PQQ, 30 to 80 parts of cranberry powder and 40 to 100 parts of an isoflavone extract, and the content of the pyrroloquinoline quinone PQQ is 2 to 5 parts, the content of the cranberry powder is 30 to 80 parts, and the content of the isoflavone extract is 40 to 100 parts. The pyrroloquinoline quinone PQQ, the cranberry powder and the isoflavone extract in a specific formula have the effect of synergistically improving the levels of anti-muller test tube hormone and superoxide dismutase, and the health food prepared from the pyrroloquinoline quinone PQQ, the cranberry powder and the isoflavone extract can improve sleep, improve urinary tract infection of middle-aged women, delay ovarian aging and the like.

The present invention discloses the application of MY-1B in the preparation of drugs for improving ovarian senescence, belonging to the technical field of biomedicine, aiming to solve the problem of how to effectively delay ovarian senescence and improve ovarian function. Experiments have proved that during ovarian senescence, the mRNA m<supgt;5< / supgt;C modification level and the expression level of methyltransferase in ovarian granulosa cells increase. Supplementation with MY-1B can improve the condition caused by mRNA m Nsun2 expression.

The application discloses application of NCOA7 circular RNA nanoliposome in preparation of a drug for treating premature ovarian failure or ovarian reserve function decline, and belongs to the technical field of biological medicine.The present application proves that nuclear receptor coactivator 7 (NCOA7) can relieve ovarian aging and significantly improve the ovarian function and fertility of DOR patients.The present application finds that NCOA7 circular RNA nanoliposome treatment can significantly improve the NCOA7 protein expression level of DOR female ovarian granulosa cells, improve the aging phenotype and growth rate of the DOR female ovarian granulosa cells, and has no significant influence on the biological characteristics of the ovarian granulosa cells, thereby providing a new scheme for rescuing the ovarian function and improving the fertility of DOR women.

The application relates to application of semaglutide in preparation of a medicine for treating or delaying ovarian aging, and through a natural aging mouse model, a cell aging model and transcriptome analysis, it is first proved that semaglutide can significantly increase the number of follicles and reduce the level of aging markers, and from a molecular level, it is revealed that the mechanism of realizing multi-target point delay of ovarian aging is that semaglutide realizes multi-target point delay of ovarian aging through regulating an adipocyte cytokine signal pathway, inhibiting excessive cell division and regulating an NF-kappa B signal pathway. As a marketed drug, semaglutide has clear safety, a long half-life and high patient compliance, and has a significant clinical conversion prospect. The application breaks through the limitation that existing hormone replacement therapy and assisted reproductive technology can only treat symptoms or solve the problem of fertility, provides a first drug intervention strategy which can fundamentally delay the process of follicle depletion, and fills the blank in the field of ovarian aging treatment.

The invention discloses an application of a small molecular compound and an analogue thereof in treating ovarian aging diseases. It is found for the first time that the exogenous supplementary adenosine or the analogues thereof can effectively recover or improve the ovarian function and can prevent and inhibit ovarian fibrosis, and therefore the exogenous supplementary adenosine or the analogues thereof can be used as potential drugs for recovering the female fertility.

The invention provides an FSH33 peptide modified DNA tetrahedron nano delivery system as well as a preparation method and application thereof, and aims to provide a safe and efficient antioxidant nano drug and optimize the enrichment efficiency to promote ovarian aging and ovarian tissue damage repair. The system is a nano-scale nucleic acid compound composed of a tetrahedral DNA frame structure and an FSH targeting peptide. The tetrahedral DNA frame structure is a microscopic 3D stereoscopic tetrahedral structure formed by self-assembly of DNA single chains of a specific nucleic acid sequence, wherein each side extends out of a viscous end used for being connected with an FSH peptide. The research finds that the DNA tetrahedron can safely and effectively improve the ovarian endocrine function, ovarian reserve, fertility and the like of mice in a drug protection group, has no obvious toxic or side effect on all organs and tissues of the whole body, and can promote the repair of ovarian oxidative damage.

The invention relates to an effect of an REV-ERBalpha agonist SR9009 in the aspect of delaying ovarian senescence, and aims at the problem of fertility decline caused by cliff-type decline of ovarian functions of women over 35 years old, the SR9009 is applied to activate an REV-ERBalpha circadian rhythm signal channel in ovarian tissues, inhibit excessive autophagy of granular cells and maintain a primordial follicle dormancy state, so that the agonist SR9009 can be used for delaying ovarian senescence. Therefore, the original follicle depletion speed is delayed, follicle storage is maintained, and the ovary reproductive function cycle is prolonged. The effect is verified by a mammal model: REV-ERBalpha protein expression in an ovary of an aging individual is reduced, rhythmicity expression is disordered, autophagy of granulosa cells can be effectively inhibited in the ovary of the aging individual intervened by the SR9009, and the number of residual primordial follicles and the number of total follicles are obviously greater than those of an untreated control group. The invention provides an innovative treatment strategy of targeted rhythm regulation and control for clinical intervention of ovarian aging.

The application relates to the field of biotechnology, and particularly relates to an application of Bacteroides ovatus in ovarian aging; the application comprises: taking low-abundance Bacteroides ovatus as a biomarker of ovarian aging; the application comprises using Bacteroides ovatus in a medicine for delaying ovarian aging; the application further comprises using a fermentation product of Bacteroides ovatus in the medicine for delaying ovarian aging; it is found through experiments that there is a significant difference in Bacteroides ovatus in mice with different degrees of ovarian aging, and it is found through subsequent experiments that Bacteroides ovatus has the effects of significantly increasing the number of oocytes, up-regulating anti-Mullerian hormone, up-regulating the level of estradiol and down-regulating the level of follicle-stimulating hormone, which indicates that Bacteroides ovatus can be used in the medicine for delaying ovarian aging.

The invention relates to the technical field of biological medicines, and particularly discloses a composition containing resveratrol and application of the composition in preparation of a product with an ovarian aging resisting effect. The resveratrol-containing composition is characterized by comprising resveratrol and a traditional Chinese medicine extract, wherein the weight ratio of the resveratrol to the traditional Chinese medicine extract is (10-20): 100. Researches show that the composition containing the resveratrol and the traditional Chinese medicine extract has an ovarian aging resisting effect; therefore, the composition provided by the invention has important application value when being used as an active ingredient for preparing medicines or health-care products with an ovarian aging resisting effect.

The invention relates to the technical field of biotechnology and animal genetic breeding, and aims at providing application of an SLC2A9 gene in identifying the chicken ovary state. The second purpose of the invention is to provide an application of the SLC2A9 gene or the expression product thereof as a marker in identifying or evaluating the follicular atresia degree of chicken. The third purpose of the invention is to provide the application of the SLC2A9 gene or the expression product of the SLC2A9 gene as a marker in identifying or evaluating the senescence state of the chicken ovary. The invention finds that the SLC2A9 gene or the expression product thereof can be used as a specific biomarker for evaluating the chicken ovarian development state, follicular atresia degree and ovarian aging degree. By detecting the expression level, the objective and quantitative evaluation of the ovarian physiological status of the individual chicken can be realized, and the limitation of only depending on external phenotype observation is overcome.

The invention provides application of arachidonic acid in delaying reproductive aging, and particularly relates to the technical field of reproductive health. The invention provides application of arachidonic acid in preparation of a product for delaying reproductive aging and / or prolonging the reproductive period. By taking caenorhabditis elegans and mice as examples, the arachidonic acid can obviously activate reproductive aging gonad lysosome, protect oocyte quality and prolong reproductive cycle, thereby delaying reproductive aging. The invention provides a new application prospect of arachidonic acid in the aspects of delaying ovarian aging and protecting fertility.

The present invention provides a method for preparing ovarian stem cells and their use in treating ovarian aging. More specifically, the present invention screens and prepares ovarian stem cells from ovaries and isolates LRP-C5, a peptide with promising therapeutic effects on ovarian aging, from deer antler antler polypeptides. Both, when used alone or in combination, are effective in treating ovarian aging in rats and have promising application prospects.

The invention provides a transdermal absorption composition containing six active peptides and application of the transdermal absorption composition. The transdermal absorption composition is prepared from 0.5 to 5 parts of acetyl hexapeptide-8, 0.5 to 5 parts of decapeptide-4, 0.5 to 5 parts of oligopeptide-1, 1 to 10 parts of glycoprotein, 1 to 8 parts of serum protein, 5 to 20 parts of soluble collagen, 3 to 12 parts of mannitol, 2 to 10 parts of trehalose, 1 to 5 parts of caprylyl glycol and 5 to 25 parts of butanediol. The composition is used for preparing transdermal absorption products for improving ovarian functions and delaying ovarian aging. Through a penetration enhancer combination and raw material modification process, the technical problems that polypeptide is difficult to transdermal and easy to inactivate are effectively solved, and the skin permeability and stability of active ingredients are improved, so that the ovarian function is improved through synergistic interaction.

This invention discloses an S-estrol composition for delaying ovarian aging and its uses, relating to the fields of biomedicine and health products. The S-estrol composition for delaying ovarian aging comprises, by weight, the following components: 1-5 parts S-estrol, 2-8 parts soy isoflavones, 3-10 parts coenzyme Q10, 2-6 parts vitamin E, 4-12 parts vitamin C, 0.01-0.05 parts folic acid, 0.1-0.3 parts zinc source, 0.5-1.5 parts anti-aging protective agent, 50-80 parts carrier, and 10-15 parts purified water. This invention uses high-purity S-estrol as the core, combined with soy isoflavones, coenzyme Q10 and a variety of antioxidant nutrients in a scientific formulation to form a synergistic system for estrogen receptor signal regulation and antioxidant defense. By constructing a complex antioxidant network and introducing novel anti-aging protectants for synergistic effect, the activity of antioxidant enzymes tends to increase and the level of lipid peroxidation tends to decrease, thereby improving the oxidative stress state in ovarian cells as a whole.

The invention provides an application of an E3 ubiquitin ligase RLIM gene inhibitor in preparation of a medicine for treating ovarian aging or injury. Experiments find that the expression level of the RLIM gene in the ovary is positively correlated with the aging degree, and the expression of the RLIM gene is remarkably improved along with age increase. In-vivo and in-vitro experiments show that ovarian granular cell senescence can be effectively delayed and ovarian functions can be improved by inhibiting RLIM expression, and particularly, the proportion of atresia follicles is reduced, the number of healthy follicles is increased, and serum AMH and E2 levels are remarkably improved. The pharmaceutical composition provided by the invention comprises a siRNA inhibitor (preferably, siRLIM-2) of specific targeting RLIM and a nano-liposome carrier, and efficient targeting delivery can be realized through tail vein injection. The treatment scheme has no toxic effect on important organs, is high in safety, and provides a new effective means for treatment of ovarian aging and related diseases.

The invention relates to application of salvianolic acid B in promoting fertility of elderly women and reducing ovarian fibrosis. It is found that salvianolic acid B can inhibit ovarian fibrosis in a targeted mode, reverse ovarian function decline, regulate ovarian aging in a multi-dimensional mode and repair fertility and reserve functions, and salvianolic acid B is a natural component derived from radix salviae miltiorrhizae, is high in safety and breaks through the contradiction between the curative effect and the risk. Therefore, the application of the invention effectively solves the technical bottlenecks of the existing therapy in the aspects of ovarian fibrosis targeting, ovarian function multi-dimensional repair and drug safety, and provides a natural, safe and efficient treatment strategy for ovarian aging-related infertility and fibrosis diseases.

The invention discloses an application of Reco18 in preparation of a product for improving skin glossiness, smoothness, irregular menstruation, sleep or ovarian aging. Reco18 is a nutritional supplement preparation, the core component Reco18 is a component of follicular fluid, the research shows that the Reco18 can improve the skin condition of women and delay ovarian aging, specifically, the Reco18 can remarkably improve the skin glossiness, roughness and smoothness of women, effectively relieve sleep disorder, relieve dysmenorrhea and delay ovarian aging, and the Reco18 can be used for preparing the follicular fluid. The menstrual color is ruddy, and the safety is good.

The invention provides an application of a reverse transcription transposon ERV1 as a biomarker in evaluation of ovarian aging of a subject and / or delaying of ovarian aging of the subject. The invention proves that the female ovarian senescence activity can be evaluated through the mRNA expression level of ERV1, the expression level of ERV1 in ovaries of infertility patients of old women and menopausal women can be conveniently and quickly detected, the ovarian senescence state can be reflected, and a basis is provided for a molecular target for intervening ovarian senescence.

The present invention discloses the application of the PLPP3 gene in regulating autophagy in human ovarian granulosa cells, belonging to the field of cell engineering and genetic engineering technology. The present invention discovered for the first time that overexpression of the PLPP3 gene can significantly increase the levels of autophagy and apoptosis in granulosa cells; while interfering with the expression of the PLPP3 gene significantly reduces the levels of autophagy, apoptosis and cell activity in granulosa cells. It was also found that the PLPP3 protein level was low in the ovarian tissue of middle-aged people; while the PLPP3 protein level was high in the ovarian tissue of the elderly. The PLPP3 protein level was positively correlated with the degree of human ovarian aging and can be used as a marker to diagnose / evaluate the level of human ovarian aging. The present invention has great application value in studying the mechanism of the influence of autophagy regulation on ovarian follicle development, reproductive capacity and ovarian-related diseases, and has important clinical value in protecting ovarian function and treating ovarian-related diseases.

The present application belongs to the field of animal nutrition and feed science and technology, and particularly relates to a honeysuckle by-product fermented feed as well as a preparation method and application thereof. The present application uses mature branch and leaf honeysuckle by-products as raw materials, wheat bran as an auxiliary material, and adds a bacteria-enzyme fermenting agent compounded by specific composite enzymes and composite microorganisms to obtain a functional fermented feed through anaerobic solid-state sealed fermentation. The present application has simple process and controllable cost, can efficiently degrade raw material crude fiber, increase crude protein content, release active ingredients, and realize high-value utilization of honeysuckle by-products. When added into the diet of laying hens in the later stage of egg production at a suitable ratio, the present application can significantly improve the egg production rate, enhance the body's antioxidant and anti-inflammatory capacity, improve the intestinal barrier and microecology, delay ovarian aging, and prolong the egg production period, thereby providing a new technology for green and healthy breeding of laying hens.

The invention relates to an application of light waves in preparation of a medical instrument for treating ovarian aging. The medical instrument generates light waves with energy of 2-50J / cm < 2 > and wavelength of 650nm + / -10nm. The propagation direction of guided light waves in vitro faces the ovary of a tested animal, and verification shows that the activity, proliferation and hormone secretion of KGN cells are remarkably protected, meanwhile, H2O2-induced KGN cell apoptosis is inhibited, the unbalance condition of pro-inflammatory and anti-inflammatory cytokines in an aged mouse is recovered, the mitochondrial function of the ovary of the aged mouse is improved, and the curative effect of the ovary of the aged mouse is improved. The characteristics of reproduction, endocrine and the like of naturally aged ovaries are effectively improved, and the ovarian function of reproductive aging (such as premature ovarian failure) can be recovered.

Provided herein are compositions and methods for reducing or preventing ovarian aging comprising: administering to a subject in need of a reduction or prevention of ovarian aging an effective amount of an SGLT2 antagonist. Examples of SGLT2 antagonists include canagliflozin, bexagliflozin, dapagliflozin, empagliflozin, ertugliflozin, sotagliflozin, phlorizin, or combinations thereof.

The application provides use of an inhibitor targeting IL-11 or an IL-11 receptor in preparation of a drug for delaying ovarian aging, and first discloses and proves that an inflammatory factor interleukin-11 (IL-11) is a core target point for driving ovarian aging and an increase in ovarian matrix stiffness and fibrosis under pathological conditions such as chemotherapy damage and polycystic ovary syndrome, and the interleukin-11 promotes excessive secretion of collagen by activating an IL-11RA / ERK signal axis in ovarian fibroblasts. Based on this, the application provides a new use of an inhibitor (such as specific siRNA and a neutralizing antibody) targeting IL-11 or the receptor thereof in preparation of a related therapeutic drug. In particular, a liposome nanoparticle loaded with IL-11 siRNA can effectively reduce ovarian stiffness, reduce fibrosis, significantly improve follicle reserve, hormone level and fertility, and successfully reverse the ovarian aging phenotype in old mice, rats and various disease models. The application provides a new effective target point, a treatment strategy and a product prototype with a transformation potential for intervention on ovarian aging and related diseases.

The present invention relates to the field of biomedicine technology, and more specifically, to an endometrial stem cell drug and its preparation process. The present invention optimizes the culture medium components of endometrial stem cells to obtain a more optimal culture medium; the endometrial stem cell culture medium comprises DMEM, VEGF, and β-ecdysterone. The concentration of the VEGF is 20 ng / ml, and the concentration of the β-ecdysterone is 20 ng / ml. Endometrial stem cells prepared using the culture medium of the present invention have a stronger proliferation ability and better anti-ovarian aging and ovarian repair effects.

The invention relates to a composition containing stem cells and application of the composition in ovarian aging resistance. According to the invention, the polypeptide TP-TOF with ovarian aging resistance is separated and screened from placenta, and the polypeptide can effectively reduce apoptosis of ovarian granular cells. The polypeptide can effectively promote recovery of ovarian estradiol and follicular poietin levels of rats independently or in combination with stem cells, can remarkably prolong the estrus period, reduce the estrus interval, reduce follicle apoptosis and promote follicle generation, and has a wider application prospect.

The present invention discloses an application of Tgfbr2 in the preparation of ovarian function protection drugs, belonging to the field of tumor fertility protection technology. Specifically, a certain dose of AdV-Tgfbr2 is injected in situ into the ovaries of the test mammals by gene therapy, and the overexpression level of Tgfbr2 is detected. The purpose of reconstructing ovarian function is achieved by repairing the damaged parts. Therefore, the AdV-Tgfbr2 recombinant vector and its pharmaceutical preparation can protect ovarian function without affecting the anti-cancer effect. As a new drug, it plays an important role in repairing ovarian damage and / or resisting and delaying ovarian aging and / or improving ovarian reserve function and / or reconstructing ovarian function.

The application belongs to the technical field of gel materials, and specifically discloses an anti-ovarian aging gel and a preparation method thereof, which comprises the following components in percentage by mass: 0.05-0.2% of lactic acid, 0.1-0.4% of a stabilizer, 0.2-0.6% of tocopherol acetate, 0.2-0.6% of 1,2-hexanediol, 0.3-0.6% of a sustained-release agent, 0.9-1.2% of hydrolyzed lupin protein, 0.8-1.6% of hydrolyzed royal jelly protein, 0.75-1.3% of cortex moutan extract, 1-1.5% of a thickening agent, 0.5-2% of gelatin, 0.5-1.2% of beeswax, and the balance of water. The composition disclosed in the application takes the hydrolyzed lupin protein, the hydrolyzed royal jelly protein and the cortex moutan extract as main active ingredients, and under the joint action of the lactic acid, the stabilizer, the tocopherol acetate, the 1,2-hexanediol, the sustained-release agent, the thickening agent, the gelatin and the beeswax, the gel obtained can effectively improve the content of progesterone and E2 and has a good anti-ovarian aging effect.